CN101151030A - 用于治疗血栓的包括至少一种直接凝血酶抑制剂的组合物 - Google Patents

用于治疗血栓的包括至少一种直接凝血酶抑制剂的组合物 Download PDF

Info

Publication number
CN101151030A
CN101151030A CNA2006800108359A CN200680010835A CN101151030A CN 101151030 A CN101151030 A CN 101151030A CN A2006800108359 A CNA2006800108359 A CN A2006800108359A CN 200680010835 A CN200680010835 A CN 200680010835A CN 101151030 A CN101151030 A CN 101151030A
Authority
CN
China
Prior art keywords
chloro
carbonyl
pharmaceutical composition
base
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800108359A
Other languages
English (en)
Chinese (zh)
Inventor
保罗·A·赖利
詹姆斯·C·吉尔伯特
托马斯·H·米勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36423564&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101151030(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CN101151030A publication Critical patent/CN101151030A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA2006800108359A 2005-03-29 2006-03-27 用于治疗血栓的包括至少一种直接凝血酶抑制剂的组合物 Pending CN101151030A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05006711.5 2005-03-29
EP05006711 2005-03-29

Publications (1)

Publication Number Publication Date
CN101151030A true CN101151030A (zh) 2008-03-26

Family

ID=36423564

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800108359A Pending CN101151030A (zh) 2005-03-29 2006-03-27 用于治疗血栓的包括至少一种直接凝血酶抑制剂的组合物

Country Status (19)

Country Link
US (2) US20060222640A1 (https=)
EP (1) EP1885354A2 (https=)
JP (1) JP2008534552A (https=)
KR (1) KR20070116936A (https=)
CN (1) CN101151030A (https=)
AR (1) AR056291A1 (https=)
AU (1) AU2006228600A1 (https=)
BR (1) BRPI0608656A2 (https=)
CA (1) CA2602563A1 (https=)
CL (1) CL2010000395A1 (https=)
EA (1) EA015122B1 (https=)
IL (1) IL186267A0 (https=)
MX (1) MX2007010664A (https=)
NO (1) NO20074149L (https=)
NZ (1) NZ562775A (https=)
TW (1) TW200722089A (https=)
UA (1) UA92603C2 (https=)
WO (1) WO2006103206A2 (https=)
ZA (1) ZA200706698B (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102250099A (zh) * 2011-05-16 2011-11-23 中国药科大学 一类非肽类抗凝血酶抑制剂、其制法以及医药用途
CN103402527A (zh) * 2011-01-25 2013-11-20 鲁汶大学 用于细胞移植的组合物和方法
CN103463083A (zh) * 2008-11-11 2013-12-25 贝林格尔.英格海姆国际有限公司 使用达比加群酯或其盐治疗或预防血栓形成且与常规华法林疗法相比具有改良有效性的方法
WO2017080043A1 (zh) * 2015-11-13 2017-05-18 谭惠娟 一种抗血栓组合物
CN108236612A (zh) * 2016-12-27 2018-07-03 李志忠 用于冠脉介入手术中抗凝的组合产品及其用途
CN115192691A (zh) * 2022-08-31 2022-10-18 晓恩医药包装材料(安庆)有限公司 一种阿加曲班注射液及预灌封注射器

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906894B1 (en) 2000-07-27 2014-12-09 Thomas N. Thomas Methods for preventing and treating thrombotic disorders
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
DE10339862A1 (de) * 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
IL159273A0 (en) * 2003-12-09 2004-06-01 Transpharma Medical Ltd Transdermal delivery system for sustained release of polypeptides
US20080274166A1 (en) * 2005-06-10 2008-11-06 Transpharma Medical Ltd. Patch for Transdermal Drug Delivery
AR062057A1 (es) * 2006-07-17 2008-10-15 Boehringer Ingelheim Int Uso de los inhibidores directos de la trombina
WO2008043759A1 (en) * 2006-10-10 2008-04-17 Boehringer Ingelheim International Gmbh Physiologically acceptable salts of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester
DE102006051625A1 (de) 2006-11-02 2008-05-08 Bayer Materialscience Ag Kombinationstherapie substituierter Oxazolidinone
CA2704164A1 (en) * 2007-10-29 2009-05-07 Transpharma Medical Ltd. Vertical patch drying
WO2010013231A2 (en) * 2008-07-29 2010-02-04 Yeda Research And Development Co. Ltd. Modulation of coagulation factors and effectors of same for control of transplant organ size
WO2010029552A1 (en) * 2008-09-10 2010-03-18 Transpharma Medical Ltd. Transdermal delivery of oligosaccharides
JP2013510072A (ja) 2008-11-11 2013-03-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 従来のワルファリン治療に対して安全性プロフィールが改善されたダビガトランエテキシレートまたはその塩を使用して血栓症を治療または予防するための方法
AR074108A1 (es) * 2008-11-11 2010-12-22 Boehringer Ingelheim Int Metodo para tratar o prevenir la trombosis utilizando etexilato de dabigatran o una sal del mismo con eficacia mejorada sobre la terapia convencional con warfarina
RU2011132125A (ru) 2008-12-30 2013-02-10 Тромбологик Апс Способы идентификации критических пациентов с повышенным риском развития органной недостаточности и соединения для их лечения
EP2806879B1 (en) 2012-01-25 2019-03-06 Université Catholique de Louvain Compositions and methods for cell transplantation
US20130345262A1 (en) 2012-06-25 2013-12-26 Boehringer Ingelheim International Gmbh Method for prevention of stroke
EP2722033A1 (en) * 2012-10-19 2014-04-23 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical Compositions of Dabigatran Free Base
EP2722034B1 (en) * 2012-10-19 2020-09-16 Sanovel Ilac Sanayi ve Ticaret A.S. Oral pharmaceutical formulations comprising dabigatran
ES2759228T3 (es) 2013-07-05 2020-05-08 Univ Catholique Louvain Medio acondicionado de células madre de hígado de adultos y su uso en el tratamiento de trastornos del hígado
DE102014108210A1 (de) * 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
US12251377B2 (en) 2019-03-06 2025-03-18 University Of Rochester Anticoagulant compositions and uses thereof
US11654036B2 (en) 2020-05-26 2023-05-23 Elixir Medical Corporation Anticoagulant compounds and methods and devices for their use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) * 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
US5510330A (en) * 1994-03-25 1996-04-23 Boehringer Mannheim Gmbh Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof.
NZ286082A (en) * 1995-03-15 1998-09-24 Behringwerke Ag Method of treating acute myocardial infarction with hirudin and acetylsalicylic acid in patients not undergoing thrombolytic treatment
FR2744918B1 (fr) * 1996-02-19 1998-05-07 Sanofi Sa Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique
PE121699A1 (es) * 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
US6414008B1 (en) * 1997-04-29 2002-07-02 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions
DE19834751A1 (de) * 1998-08-01 2000-02-03 Boehringer Ingelheim Pharma Disubstituierte bicyclische Heterocyclen, ihre Herstellung und ihre Verwendung als Arzneimittel
GB9930540D0 (en) * 1999-12-23 2000-02-16 Rhone Poulenc Rorer Pharma Chemical compounds
GB0014134D0 (en) * 2000-06-10 2000-08-02 Astrazeneca Ab Combination therapy
KR20040044514A (ko) * 2001-09-14 2004-05-28 미쯔비시 웰 파마 가부시키가이샤 항혈전약과 피라졸론 유도체의 조합 약제
KR101005716B1 (ko) * 2002-03-07 2011-01-05 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 ３－［（２－｛［４－（헥실옥시카보닐아미노－이미노-메틸）－페닐아미노］－메틸｝－１－메틸－１ｈ－벤즈이미다졸－５－카보닐）－피리딘－２－일－아미노］ 프로피온산 에틸에스테르의 경구 투여 형태
DE10235639A1 (de) * 2002-08-02 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Prodrugs von 1-Methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carbonsäure-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amid, ihre Herstellung und ihre Verwendung als Arzneimittel
AU2004231306A1 (en) * 2003-04-24 2004-11-04 Boehringer Ingelheim International Gmbh Use of dipyridamole or mopidamole for treatment and prevention of thrombo-embolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of thrombin receptors

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103463083A (zh) * 2008-11-11 2013-12-25 贝林格尔.英格海姆国际有限公司 使用达比加群酯或其盐治疗或预防血栓形成且与常规华法林疗法相比具有改良有效性的方法
CN103402527A (zh) * 2011-01-25 2013-11-20 鲁汶大学 用于细胞移植的组合物和方法
CN103402527B (zh) * 2011-01-25 2016-04-20 鲁汶大学 用于细胞移植的组合物和方法
CN102250099A (zh) * 2011-05-16 2011-11-23 中国药科大学 一类非肽类抗凝血酶抑制剂、其制法以及医药用途
CN102250099B (zh) * 2011-05-16 2013-10-16 中国药科大学 一类非肽类抗凝血酶抑制剂、其制法以及医药用途
WO2017080043A1 (zh) * 2015-11-13 2017-05-18 谭惠娟 一种抗血栓组合物
CN108236612A (zh) * 2016-12-27 2018-07-03 李志忠 用于冠脉介入手术中抗凝的组合产品及其用途
CN115192691A (zh) * 2022-08-31 2022-10-18 晓恩医药包装材料(安庆)有限公司 一种阿加曲班注射液及预灌封注射器

Also Published As

Publication number Publication date
WO2006103206A2 (en) 2006-10-05
US20100184729A1 (en) 2010-07-22
IL186267A0 (en) 2008-01-20
CL2010000395A1 (es) 2010-08-20
JP2008534552A (ja) 2008-08-28
WO2006103206A3 (en) 2007-01-11
BRPI0608656A2 (pt) 2010-01-19
US20060222640A1 (en) 2006-10-05
TW200722089A (en) 2007-06-16
NZ562775A (en) 2011-03-31
EA015122B1 (ru) 2011-06-30
KR20070116936A (ko) 2007-12-11
MX2007010664A (es) 2007-12-12
NO20074149L (no) 2007-12-11
EA200701841A1 (ru) 2008-02-28
AR056291A1 (es) 2007-10-03
EP1885354A2 (en) 2008-02-13
UA92603C2 (ru) 2010-11-25
AU2006228600A1 (en) 2006-10-05
CA2602563A1 (en) 2006-10-05
ZA200706698B (en) 2008-12-31

Similar Documents

Publication Publication Date Title
CN101151030A (zh) 用于治疗血栓的包括至少一种直接凝血酶抑制剂的组合物
US12042494B2 (en) Compositions and methods for treating centrally mediated nausea and vomiting
ES2380704T3 (es) Metanosulfonato de éster etílico de ácido 3-[(2-{[4-(hexiloxicarbonilamino--imino-metil)-fenilamino]-metil}-1-metil-1H-bencimidazol-5-carb3onil)-piridin-2-il-amino]-propiónico
CN105263498B (zh) 赛尼克韦罗组合物及其制备和使用方法
TW201210593A (en) Compositions and methods for treating centrally mediated nausea and vomiting
ES2729677T3 (es) Esferoides de fármacos recubiertos y sus usos para eliminar o reducir condiciones, como la emesis y la diarrea
CN103917231A (zh) 组蛋白脱乙酰酶抑制剂与苯达莫司汀的联合制剂及其用途
US12097284B2 (en) Mycophenolate oral suspension
US11696895B2 (en) Fine particle coating (drug-containing hollow particle and method for manufacturing same)
KR101469326B1 (ko) 베포타스틴 또는 이의 약학적으로 허용가능한 염과 수불용성 염기성 물질을 포함하는 약제학적 제제
CN107613984A (zh) 药物组合物及其用途
JPWO2013172297A1 (ja) ６，７−不飽和−７−カルバモイルモルヒナン誘導体含有製剤
WO2019008605A1 (en) NEW PHARMACEUTICAL CO-CRYSTAL OF DABIGATRAN ETXILATE
HK1119932A (en) Combinations comprising at least one direct thrombin inhibitor for the treatment of thrombosis
TW202541796A (zh) 用於治療失樂症的組成物及方法
JP4521554B2 (ja) シクロスポリン製剤
HK40116611A (zh) 用於治疗癌症的包含cdk2抑制剂和cdk4抑制剂的方法和给药方案
HK40031570A (en) Novel fine particle coating (drug-containing hollow particle and method for manufacturing same)
KR20170139966A (ko) 흡습성이 개선된 고협압 및 발기부전 치료제를 함유한 약제학적 복합 조성물
HK1228787A1 (en) Compositions and methods for treating centrally mediated nausea and vomiting
HK1171391A (en) Compositions and methods for treating centrally mediated nausea and vomiting

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1119932

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20080326

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1119932

Country of ref document: HK